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Abstract. Background/Aim: Endometrial hyperplastic
polyps (EHP) may progress to endometrial carcinoma (EC)
if left untreated. We aimed to prospectively investigate the
efficacy of the low-dose levonorgestrel intrauterine system
(LNG-IUS) as therapy for EHP with malignant potential.
Patients and Methods: In total, 37 women with EHP
underwent therapy with LNG-IUS containing 13.5 mg
levonorgestrel for six months or 4-10 weeks depending on
whether the EHP was characterized (by D-score analysis) as
low- to medium-risk (n=33) or high-risk (n=4) of coexistent
or future EC. Therapy response was defined as complete
clearance of hyperplastic glands in post-therapy endometrial
biopsy. Results: All women with low- to medium-risk EHP
obtained therapy response, whereas only 1 out of 4 with high-
risk EHP responded to therapy. None of the women were
diagnosed with EC during the study and no serious adverse
events occurred. Conclusion: Low-dose LNG-IUS represents
a promising therapy for selected women with EHP.
Endometrial polyps (EP) frequently occur in pre, peri and
postmenopausal women and may be diagnosed in 20–30% of
patients with abnormal uterine bleeding (1). Although most EP
are benign, a systematic review has reported premalignant
(hyperplastic) and malignant changes to be present in 0.2-
23.8% and 0-12.9% of the cases, respectively (2).
Previous research has mainly focused on the oncogenic
potential of macroscopically visible polyps, related to clinical
characteristics such as polyp size, symptoms, use of hormonal
medication, patient’s age, BMI and menopausal status, and
whether such polyps should be hysteroscopically resected or
not (3, 4). More recently, the coexistence of hyperplastic
endometrial polyps (EHP) with endometrial hyperplasia (EH)
and endometrial carcinoma (EC) in the surrounding non-
polypoid endometrium, has gained increasing attention (5, 6).
Despite the fact that management of malignant EP now
coincides with current therapy recommendations for EC, no
therapy guidelines are available when EHP are detected in
endometrial biopsies or polypectomy specimens. However,
the described tendency of EHP to coexist with multifocal
hyperplastic lesions in the non-polypoid endometrium and
the suggested causal connection between polyp formation
with and unopposed estrogen stimulation of the endometrium
indicates a potential role for hormonal therapy with progestin
in these women.
The pathogenesis of EP is not fully understood. In contrast,
it is well established that non-polypoid EH is an estrogen-
dependent precursor lesion to EC with up to 30% risk of
malignant progression (7). Oral and intrauterine progestin has
been routinely and successfully used as treatment for this
condition since decades and randomized trials have shown
higher regression rates for intrauterine compared to oral
progestin therapy in patients with non-atypical EH (8-11).
So far, progestin therapy is poorly investigated in patients
with EP and EHP although such studies have been requested
(12, 13). A Cochrane review concluded that the LNG-IUS has
a preventive effect and reduces the incidence of benign polyp
formation in women undergoing tamoxifen therapy for breast
cancer (14). A former retrospective observational study
demonstrated that all women diagnosed with low- to medium-
risk EHP were cured after six months treatment by the high-
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dose LNG-IUS (Mirena®, 52 mg, Bayer Pharmaceuticals,
Berlin, Germany), independent of diagnosis (simple, complex,
or atypical hyperplasia), whereas only 25% of patients
receiving oral progestin obtained response (15). Sustained
regression of EHP for as long as the LNG-IUS (FibroPlant®
APCOR Research, Ghent, Belgium) remained in situ was
described in a single case report by Janssen et al. (16).
In a recent study, low-dose LNG-IUS (Jaydess®, Bayer
Pharmaceuticals, Berlin, Germany), with a total content of 13.5
mg levonorgestrel, was successfully given as therapy for six
months in women with low- and medium-risk EH (17).
Compared to the high-dose LNG-IUS, the thinner insertion tube
and smaller T-frame might prove beneficial for young
nulliparous women and for elderly women with stenotic cervical
channel simultaneously reducing systemic side-effects to a
minimum. Thus, the main objective of the current pilot study
was, as the first ever, to investigate if the low-dose LNG-IUS
is sufficient therapy for EHP with various malignant potential.
Patients and Methods
The study was designed as a prospective, multicenter, pilot study to
assess the efficacy of low-dose LNG-IUS as therapy for EHP. LNG-
IUS 13.5 mg is approved as a contraceptive for up to three years use
(18). The in vivo LNG-release rate declines progressively after insertion
(19). After 24 days, 60 days and 3 years the LNG release rate was
calculated to be 14 μg/24 h, 10 μg/24 h and 5 μg/24 h, respectively.
Average LNG release rate over three years was 6 μg/24 h (19). Pre-
and post-menopausal women with histologically confirmed EHP were
eligible for study inclusion. Histopathological material (baseline biopsy)
from the endometrium, obtained prior to study inclusion, was sampled
by Pipelle (Pipelle, Laboratoire CCD, Paris, France) (n=22), D&C
(dilatation and curettage) (n=10), or hysteroscopic transcervical
resection (n=6). All women had consulted their gynecologists due to
abnormal uterine bleeding, and were diagnosed with menometrorrhagia
(n=20), menorrhagia (n=5), or postmenopausal bleeding (n=13).
Endometrial thickness, measured by transvaginal ultrasound prior to
therapy, varied from 3 to 30 mm.
Enrollment. The study was open for inclusion from August 1st, 2015
to August 1st, 2017. A total of 38 women were consecutively recruited
to the study at six different gynecological outpatient clinics in northern
Norway between December 8th, 2015 and July 17th, 2017. Written
informed consent was obtained from all participants. The LNG-IUS
was inserted by the responsible gynecologist in accordance to
manufacturer’s instructions. Blood samples were obtained at inclusion
to measure s-estradiol and s-FSH. According to our laboratory
practice, these values can be used to define menopausal status.
Study participants were assigned to two different therapy groups
according to individual risk stratification, based on WHO94
classification and D-score (see Morphometric analysis (D-score)) in
baseline biopsy, concerning the probability of coexistent or future
EC. Women with low- to medium-risk hyperplastic polyps (simple
hyperplasia (SH) or complex hyperplasia (CH) and a D-score ≥0)
received conservative therapy with low-dose LNG-IUS for six
months (therapy group A). Women with high-risk hyperplastic
polyps (CH or atypical hyperplasia (AH) and a D-score <0) were
scheduled for hysterectomy and underwent therapy with low-dose
LNG-IUS for 4-10 weeks while awaiting surgery (therapy group B).
CT scan of the chest, abdomen and pelvis and a pelvic MRI scan
were performed in all women in therapy group B to exclude signs
of EC (endometrial tumor, myometrial invasion, pathological lymph
nodes, or presence of metastases).
Therapy was completed at 29th of November 2017. After
completing the study, further therapy and surveillance were
individualized and left to the patient’s gynecologist to decide.
Women in therapy group A were encouraged to keep the low-dose
LNG-IUS in situ after the end of study period if side effects were
acceptable, to provide long-term endometrial protection. No
deviations from the study protocol occurred.
Outcome measures. The primary outcome of interest was endometrial
tissue response assessed by light microscopy of repeat biopsy specimens.
As quality evidence of different sampling methods during progestin
therapy is lacking, feasibility in outpatient practice and consideration of
cost perspective led to our choice of Pipelle as sampling method for
obtaining post-therapy biopsy material in therapy group A. In group B,
therapy response was evaluated by histopathological examination of the
hysterectomy specimen.
For therapy group B, hysterectomy was performed after 4-10 weeks
and post-therapy evaluation was based on standard histopathological
examination of the hysterectomy specimen. Endometrium with
progestin effect (atrophic glands and pseudodecidualized stroma) was
defined as therapy response for both patient groups. Presence or
absence of polyps or fragments of polyps were also evaluated.
Secondary outcome was adverse events during therapy.
Histological specimens. The histopathological material (baseline
biopsies, post-therapy biopsies and hysterectomy specimens) was
received at the Department of Pathology, University Hospital of
North Norway for routine assessment. All biopsies were fixed in
buffered formaldehyde and further processed in the laboratory to
prepare standard histological sections. Microscopic assessment was
performed by a trained gynecologic pathologist (AO) and one
additional routine pathologist. EP diagnosis was made when
microscopy revealed polyps or fragments of polyps, identified by
the characteristic shape covered by surface epithelium, and/or by
fibrous stroma with thick-walled or enlarged vessels (20). In the
present study the diameter of polyps or fragments was >5 mm and
<12 mm. Hyperplastic areas within the polyps were diagnosed
according to WHO94 classification using one of the three terms:
SH, CH, or AH, which was still considered the gold standard for
evaluating EH when the study was planned and formally approved
(7, 21). Ordinary light microscopy was always followed by D-score
analysis (see Morphometric analysis (D-score)). Hysterectomy
specimens from patients in therapy group B were also sent to the
Department of Pathology, University Hospital of North Norway, for
routine examination. The entire endometrium was embedded in
paraffin blocks and evaluated for the presence of EH, EHP or EC.
Morphometric analysis (D-score). Because reproducibility of the
different classification systems for the diagnosis of EH performed
by light microscopy is still debated, the morphometric image
analysis algorithm (D-score) has been introduced in the national
routine recommendations in Norway to improve the selection of risk
groups for hyperplastic lesions. Thus, hyperplastic lesions with D-
score ≥0 are considered to be of low- to medium-risk and lesions
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with D-score <0 are associated with a high risk of coexistent or
future EC (22-24). In the original computerized morphometric
analysis study on EH, a total of 10 nuclear features and 12
architectural features were analyzed (25). Using a linear stepwise
regression analysis and discriminant analysis, three of these
quantitative features were selected as having significant independent
prognostic value and were combined into the formula called D-
score, as follows: D-score=0.6229+0.0439x (volume percentage
stroma) – 3.9934x Ln (standard deviation of shortest nuclear axis)
– 0.1592x (outer surface density glands), where Ln stands for
natural logarithm (25). The measurements were performed with a
Q-PRODIT image analysis system (version 6.1; Leica, Cambridge,
UK). The method of the D-score analysis has been described in
detail in former studies (22-24).
Ethical considerations. The current study was approved by the
Regional Committees for Medical and Health Research Ethics
(2015/381) and by the Norwegian Medicines Agency (EUDRACT
number 2015-000612-17). All participants gave written informed
consent. Insurance for the coverage of pharmaceutical injuries was
signed for all study participants.
Statistics. Descriptive statistics was performed using IMB SPSS
Statistics version 24 (IMB, Armonk, NY, USA).
Results
Patients. A total of 38 women were consecutively assigned to
therapy group A (n=34) and therapy group B (n=4). One
patient in therapy group A experienced expulsion of low-dose
LNG-IUS after 13 weeks of therapy owing to excessive vaginal
bleeding (Figure 1). Clinical and demographic data of the
women completing the study (n=37) are summarized in Table
I. Median age at diagnosis was 51 years (range=30-84 years).
Median BMI (body mass index, kg/m2) was 27.7 (range=20.1-
40.6). Altogether, 78.3% of the women were overweight (BMI
25-29.9) or obese (BMI ≥30). Classification of hyperplastic
areas (within endometrial polyps or fragments of polyps),
according to WHO94 and D-score, in baseline biopsies are
presented in Table II. Among women with D-score ≥0, none
was diagnosed with AH. However, three out of four women
with D-score <0 were diagnosed with AH and none had SH.
Response to therapy. All women (n=33) in therapy group A
obtained complete response after six months of therapy with the
LNG-IUS Jaydess. Thus, post-therapy biopsies displayed no
sign of hyperplastic areas, and only inactive or sparse atrophic
endometrial glands as well as pseudodecidualized endometrial
stroma were observed by light microscopy (Figure 2A-B).
Nevertheless, small fragments of endometrial polyps were
evident in the post-therapy biopsy of five women. The majority
of women in therapy group A (n=31) preferred to keep the
LNG-IUS in situ after completing the study. Only one out of
four women in therapy group B responded to therapy according
to histopathological investigation of the hysterectomy specimen.
The baseline biopsy diagnosis of the responding woman was
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Table I. Clinical and demographic patient characteristics of the study
cohort, n=37.
Characteristics                                                    n                         (%)
Age (years)                                                           
  <45                                                                   9                        24.3
  45-55                                                              20                        54.1
  >55                                                                   8                        21.6
BMI (kg/m2)                                                        
  Normal Weight (<25)                                      8                        21.6
  Overweight (25-29.9)                                   16                        43.2
  Obese (≥30)                                                   13                        35.1
Estradiol level (nmol/l)                                        
  <0.12                                                              15                        40.5
  0.12-0.26                                                          6                        16.2
  ≥0.27                                                              16                        43.2
Menopausal status*                                              
  Premenopausal                                              20                        54.1
  Perimenopausal                                               2                          5.4
  Postmenopausal                                             15                        40.5
Vaginal bleeding                                                  
  Menometrorrhagia                                         20                        54.1
  Menorrhagia                                                    4                        10.8
  Postmenopausal bleeding                             13                        35.1
Parity                                                                    
  0                                                                       5                        13.5
  1-2                                                                  13                        35.1
  3-4                                                                  18                        47.6
  >4                                                                     1                          2.7
Method of diagnosis                                            
  Pipelle                                                            22                        59.5
  D&C                                                                9                        24.3
  Hysteroscopic resection                                  6                        16.2
WHO94 diagnosis                                                
  SH                                                                  14                        37.8
  CH                                                                 20                        54.1
  AH                                                                   3                          8.1
D-score category                                                  
  <0                                                                     4                        10.8
  ≥0                                                                   33                        89.2
*Menopausal status was defined by serum levels of estradiol (nmol/l) and
follicle stimulating hormone (FSH) (IU/l) according to our laboratory
standard. Premenopausal, estradiol ≥0.12 FSH ≤30; Perimenopausal,
estradiol ≥0.12 FSH >30; Postmenopausal, estradiol <0.12 FSH >20.
Table II. Distribution of histological WHO94 diagnosis and D-score
categories in baseline biopsies.
WHO94 diagnosis/               n=33                          n=4                   Total
therapy group                  D-score ≥0               D-score <0                 
SH                                           14                               0                       14
CH                                          19                               1                       20
AH                                            0                               3                         3
                                               33                               4                       37
Patients with D-score ≥0 were included in therapy group A and patients
with D-score <0 were included in therapy group B. SH: Simple
hyperplasia; CH: complex hyperplasia; AH: atypical hyperplasia.
CH/D-score –0.4, and therapy duration for LNG-IUS Jaydess
prior to hysterectomy was seven weeks. The other three women
(who did not respond to therapy) were diagnosed with AH
according to baseline biopsy, and therapy duration was four, five
and 10 weeks, respectively. Although hyperplastic changes were
still evident in the hysterectomy specimens of these three
women, microscopy revealed typical progestin-induced changes
with stromal pseudodecidualization and no sign of cytological
atypia after 10 weeks of therapy (Figure 2C-D). Endometrial
polyps were seen in the hysterectomy specimen of the women
treated for five weeks. None of the included women were
diagnosed with EC during the study.
Adverse events. No serious adverse events occurred during the
study period. Adverse events reported were vaginal bleeding,
headache, and mild abdominal pain (Table III). Bleeding
disturbances were most prominent during the first three
months of therapy, and it persisted in only two women after
six months of therapy. The two women reporting headache
had sparse and short-lived symptoms. Two women decided to
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Figure 1. Flow chart showing enrollment, allocation, follow-up and analysis. Therapy response was defined as endometrium with progestin effect
(atrophic glands and pseudodecidualized stroma).
remove the LNG-IUS after six months therapy due to vaginal
bleeding (n=1) and recurrent urinary infections (n=1).
Discussion
Our pilot study is, to our knowledge, the first ever to investigate
the efficacy of low-dose LNG-IUS 13.5 mg as a therapeutic
option for EHP. The demonstrated therapy response for all the
women with low- to medium-risk EHP in our study corresponds
to the results described by Arnes et al. reporting 100%
regression for high-dose LNG-IUS 52 mg in women with EHP,
independent of risk group, after six months of therapy (15).
In contrast, only one among four women with EHP
showing high-risk hyperplasia responded to therapy after 4-
10 weeks in the current study. A higher dose requirement for
atypical lesions may be of importance although the shorter
treatment time offered to these women may also be a crucial
point. Ideally, the women with high-risk EHP should have
received LNG- IUS therapy for a longer period of time to
allow adequate evaluation of therapy response.
However, ethical considerations prevented conservative
management for these women as low- dose LNG-IUS had
never before been explored as therapy for EHP.
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Figure 2. Microphotographs of histological specimens from endometrial biopsies taken before (baseline biopsy) and after (post-therapy biopsy)
therapy with the LNG-IUS Jaydess (hematoxylin and eosin, 20× magnification). (A) Baseline biopsy. Fragments of an endometrial polyp containing
hyperplastic areas classified as complex hyperplasia. The Dscore value was 1.4. (B) Post-therapy biopsy after six months treatment showed complete
therapy response characterized by extensive glandular atrophy and pseudodecidualized stroma. No endometrial polyps or fragments of polyps were
seen. (C) Baseline biopsy. An area with tightly packed glands within a hyperplastic endometrial polyp is seen. The hyperplastic areas were classified
as atypical and the D-score value was –0.5. (D) Post-therapy biopsy (hysterectomy specimen) after 10 weeks treatment. Only one single superficial
focus of complex hyperplasia was found in the endometrium of the hysterectomy specimen. The remaining endometrium revealed complete therapy
response. No endometrial polyps or fragments of polyps were seen.  
Table III. Adverse events during therapy with LNG-IUS Jaydess.
Symptoms/Grading of adverse effects               Grade 1            Grade 2
Vaginal bleeding                                                       6                     10
Headache                                                                   2                        0
Abdominal pain                                                         0                        1
Grade 1 means adverse event ≤10 days/month, grade 2 means adverse
event >10 days/month.
In the present study we hypothesized that hyperplastic foci
within EP had the same risk of malignant progression as EH
and that these hyperplastic foci would respond to progestin
therapy in a similar manner as observed for nonpolypoid EH
(10, 17, 26). Risk-stratification of EH by D-score analysis
have been successfully used for years in our clinic and in a
recent retrospective study with long-term follow-up, these
methods were reported to be applicable as predictors of
malignant transformation in EHP as well (15).
As hyperplasia within an EP has been demonstrated to be a
strong marker of wider endometrial pathology, our results
support the rationale behind intrauterine progestin therapy for
these women. Kelly et al. have found hyperplasia in the
surrounding endometrium in more than half of the women
with EHP (5). Another study reported that over 90% of
women demonstrated residual hyperplasia in the hysterectomy
specimen, despite normal hysteroscopic view, after removal of
EP containing complex atypical hyperplasia (6). The authors
concluded that hysteroscopic evaluation of the uterine cavity
and polyp resection are insufficient for eradication of
premalignant and malignant endometrial lesions (6). On this
background, the ability of intrauterine progestin therapy to
induce strong antiproliferative effect throughout the entire
endometrial mucosa is considered advantageous over
hysteroscopic resection of such lesions alone.
Previous research on EP has mainly focused on the
malignant potential in macroscopically visible polyps available
for resection by hysteroscopy. In contrast, the present study
was designed to assess if progestin therapy is effective
treatment in women with EHP diagnosed by microscopy.
Small EP have shown to be frequently overlooked by vaginal
ultrasonography and hysteroscopy, and incidental discovery of
EP, with and without hyperplastic areas during routine
histopathological examination of endometrial biopsy
specimens, is common (15, 27). Correspondingly, EP was
suspected by vaginal ultrasonography in only nine out of 37
women in the present study population.
In the current study we defined therapy response as
complete clearance of hyperplastic glands, but presence or
absence of polyp tissue in post-therapy biopsies was also of
interest. In therapy group A, only five women had fragments
of polyps in post-therapy biopsies but no evidence of
hyperplastic areas. These women kept the low-dose LNG-
IUS in situ and underwent additional endometrial sampling
outside the study protocol 12 months after LNG-IUS
insertion. The following microscopical investigation of
biopsy material demonstrated sustained progestin effect and
no signs of EP or fragments of polyps. Thus, low-dose LNG-
IUS seems capable to induce regression of both hyperplastic
areas within EP, and EP without hyperplasia.
None of our study participants reported persisting
systemic side-effects, and the therapy was generally well
tolerated throughout the treatment period, making the low-
dose LNG-IUS optimal for long-term use. Recurrence rate
after hysteroscopic resection of EP is high (13.3%) and
hyperplastic EP recurs more frequently than benign ones
(43.6%) (28). Even though relapse during long-term follow
up was not investigated in the current study, favorable
clinical effect to prevent recurrence of EH by long-term
LNG-IUS therapy has been observed by others (29).
To conclude, we demonstrated encouraging therapy
responses for low- to medium-risk EHP after six months
therapy with low-dose LNG-IUS. Whether or not the
progestin dose provided by this IUS is too low to induce
regression of high-risk EHP, or if therapy response could
have been achieved by extending therapy duration, still
remains unclear. Such studies should be addressed by future
research with larger study populations.
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